Wang L, Li Z, Li Z, Li Y, Sun Y, Ji J, et al. Efficacy and safety of neoadjuvant intensity-modulated radiotherapy with concurrent capecitabine for locally advanced rectal cancer. Dis Colon Rectum. 2015;58:186-92 pubmed publisher

Lam S, de Groot S, Honkoop A, Jager A, ten Tije A, Bos M, et al. Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a multicentre, open-label, randomised phase 2 trial. Eur J Cancer. 2014;50:3077-88 pubmed

Schmoll H, Twelves C, Sun W, O Connell M, Cartwright T, McKenna E, et al. Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised con. Lancet Oncol. 2014;15:1481-92 pubmed publisher

Mitry E, Walter T, Baudin E, Kurtz J, Ruszniewski P, Dominguez Tinajero S, et al. Bevacizumab plus capecitabine in patients with progressive advanced well-differentiated neuroendocrine tumors of the gastro-intestinal (GI-NETs) tract (BETTER trial)--a phase II non-randomised trial. Eur J Cancer. 2014;50:3107-15 pubmed publisher

Bensch F, van Rooijen J, Schröder C, Reyners A. A 21-year-old patient with a HER2-positive colorectal cancer. Gastroenterology. 2015;148:20-1 pubmed publisher

Holck S, Nielsen H, Hammer E, Christensen I, Larsson L. IQGAP1 in rectal adenocarcinomas: localization and protein expression before and after radiochemotherapy. Cancer Lett. 2015;356:556-60 pubmed publisher

Liu X, Zhang H, Sun J, Yin C, Liu T, Yang H, et al. Correlation between expression of thymidylate synthase and clinical outcome of advanced gastric cancer treated with capecitabine alone chemotherapy. Tumour Biol. 2014;35:12409-14 pubmed publisher

Piorkowska E, Kaza M, Fitatiuk J, Szlaska I, Pawinski T, Rudzki P. Rapid and simplified HPLC-UV method with on-line wavelengths switching for determination of capecitabine in human plasma. Pharmazie. 2014;69:500-5 pubmed

Walker G, Lane N, Parekh P. Photosensitive lichenoid drug eruption to capecitabine. J Am Acad Dermatol. 2014;71:e52-3 pubmed publisher

Altaf R, Lund Brixen A, Kristensen B, Nielsen S. Incidence of cold-induced peripheral neuropathy and dose modification of adjuvant oxaliplatin-based chemotherapy for patients with colorectal cancer. Oncology. 2014;87:167-72 pubmed publisher

Ihn M, Kang S, Kim D, Oh H, Lee S, Hong S. Risk factors for bowel dysfunction after sphincter-preserving rectal cancer surgery: a prospective study using the Memorial Sloan Kettering Cancer Center bowel function instrument. Dis Colon Rectum. 2014;57:958-66 pubmed publisher

Farkouh A, Scheithauer W, Buchner P, Georgopoulos A, Schueller J, Gruenberger B, et al. Clinical pharmacokinetics of capecitabine and its metabolites in combination with the monoclonal antibody bevacizumab. Anticancer Res. 2014;34:3669-73 pubmed

Schreiber V, Kitzmueller M, Poxhofer M, Gintersdorfer S, Neudorfer C, Lichtneckert M, et al. Impact of co-administered drugs on drug monitoring of capecitabine in patients with advanced colorectal cancer. Anticancer Res. 2014;34:3371-6 pubmed

Middleton G, Silcocks P, Cox T, Valle J, Wadsley J, Propper D, et al. Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial. Lancet Oncol. 2014;15:829-40 pubmed publisher

Sunami T, Tauchi J, Sakashita K, Yukimoto K, Sawada R, Sakamoto K. [A case of S-1/CDDP-resistant recurrent gastric cancer responsive to capecitabine/CDDP]. Gan To Kagaku Ryoho. 2014;41:649-51 pubmed

Jiang Y, Mackley H, Kimchi E, Zhu J, Gusani N, Kaifi J, et al. Phase I dose escalation study of capecitabine and erlotinib concurrent with radiation in locally advanced pancreatic cancer. Cancer Chemother Pharmacol. 2014;74:205-10 pubmed publisher

Hong T, Ryan D, Borger D, Blaszkowsky L, Yeap B, Ancukiewicz M, et al. A phase 1/2 and biomarker study of preoperative short course chemoradiation with proton beam therapy and capecitabine followed by early surgery for resectable pancreatic ductal adenocarcinoma. Int J Radiat Oncol Biol Phys. 2014;89:830-8 pubmed publisher

Cooper A, Holmes H, des Bordes J, Fogelman D, Parker N, Lee J, et al. Role of neoadjuvant therapy in the multimodality treatment of older patients with pancreatic cancer. J Am Coll Surg. 2014;219:111-20 pubmed publisher

Marshall J. Maintenance therapy for colorectal cancer. Oncology (Williston Park). 2014;28:322, 324 pubmed

Roxburgh P, Lumsden G, Paul J, Harden S, Sweeting L, James A, et al. A phase I and pharmacokinetic study of capecitabine in combination with radiotherapy in patients with localised inoperable pancreatic cancer. Cancer Chemother Pharmacol. 2014;74:131-9 pubmed publisher

Barbazan J, Muinelo Romay L, Vieito M, Candamio S, Díaz López A, Cano A, et al. A multimarker panel for circulating tumor cells detection predicts patient outcome and therapy response in metastatic colorectal cancer. Int J Cancer. 2014;135:2633-43 pubmed publisher

Shi H, Jiang J, Ji J, Shi M, Cai Q, Chen X, et al. Anti-angiogenesis participates in antitumor effects of metronomic capecitabine on colon cancer. Cancer Lett. 2014;349:128-35 pubmed publisher

Tanaka H, Jotoku H, Takasaki M, Ibayashi Y, Watanabe K, Takahashi M. [Effect of capecitabine therapy on the blood levels of antiepileptic drugs - report of two cases]. Gan To Kagaku Ryoho. 2014;41:527-30 pubmed

Miyamoto M, Kirii Y, Takagi H. [A case of primary duodenal cancer recurrence successfully treated with CapeOX therapy]. Gan To Kagaku Ryoho. 2014;41:495-8 pubmed

Soldini D, Gaspert A, Montani M, Reineke T, Rogler G, Odze R, et al. Apoptotic enteropathy caused by antimetabolites and TNF-α antagonists. J Clin Pathol. 2014;67:582-6 pubmed publisher

Lynch M, Drabick J, Neves R, Fox E, Mackley H, Anderson B. Palliative effect of capecitabine and cetuximab for refractory metastatic squamous cell carcinoma of the perineum in epidermodysplasia verruciformis. Skinmed. 2014;12:54-6 pubmed

Pan W, Huang S, Zhang J, Zhao B, Wang H, Liu F, et al. Heterogeneity-related anticancer therapy response differences in metastatic colon carcinoma: new hints to tumor-site-based personalized cancer therapy. Hepatogastroenterology. 2013;60:1927-34 pubmed

Yokomizo H, Yoshimatsu K, Otani T, Osawa G, Nakayama M, Matsumoto A, et al. Practical use of capecitabine plus oxaliplatin (CAPEOX) with bevacizumab for patients with metastatic colorectal cancer that cannot expect conversion therapy. Hepatogastroenterology. 2013;60:1911-5 pubmed

Primrose J, Falk S, Finch Jones M, Valle J, O Reilly D, Siriwardena A, et al. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial. Lancet Oncol. 2014;15:601-11 pubmed publisher

Yamagiwa K, Shigematsu T, Takeda K, Shirai M, Amemori K, Sunda K, et al. [Assessment of hand-foot syndrome in cancer patients treated with capecitabine-containing chemotherapy]. Gan To Kagaku Ryoho. 2013;40 Suppl 2:161-3 pubmed

Hickey R, Mulcahy M, Lewandowski R, Gates V, Vouche M, Habib A, et al. Chemoradiation of hepatic malignancies: prospective, phase 1 study of full-dose capecitabine with escalating doses of yttrium-90 radioembolization. Int J Radiat Oncol Biol Phys. 2014;88:1025-31 pubmed publisher

Cokmert S, Demir L, Can A, Akyol M, Vedat Bayoglu I, Dirican A, et al. Capecitabine-related increased mean corpuscular volume of red blood cell may be a predictive marker of treatment response and survival in patients with metastatic colorectal cancer. J BUON. 2014;19:75-82 pubmed

Rosmarin D, Palles C, Pagnamenta A, Kaur K, Pita G, Martin M, et al. A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS. Gut. 2015;64:111-20 pubmed publisher

Abrosimov A, Berdov B, Erygin D, Kondrashova L, Lushnikov E, Nevol skikh A. [Pathomorphism of rectal cancer during neoadjuvant chemoradiotherapy]. Arkh Patol. 2013;75:27-31 pubmed

Jennings B, Willis G. How folate metabolism affects colorectal cancer development and treatment; a story of heterogeneity and pleiotropy. Cancer Lett. 2015;356:224-30 pubmed publisher

Watkins D, Starling N, Cunningham D, Thomas J, Webb J, Brown G, et al. The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancreatic adenocarcinoma. The results of a phase I/II study. Eur J Cancer. 2014;50:1422-9 pubmed publisher

Esnaola N, Chaudhary U, O Brien P, Garrett Mayer E, Camp E, Thomas M, et al. Phase 2 trial of induction gemcitabine, oxaliplatin, and cetuximab followed by selective capecitabine-based chemoradiation in patients with borderline resectable or unresectable locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2014;88:837-44 pubmed publisher

Yamada M, Shinzaki S, Nishida T, Yamada T, Fujinaga T, Yakushijin T, et al. [Concomitant use of romiplostim and chemotherapy for advanced rectal cancer associated with idiopathic thrombocytopenic purpura]. Nihon Shokakibyo Gakkai Zasshi. 2014;111:521-8 pubmed

Rosmarin D, Palles C, Church D, Domingo E, Jones A, Johnstone E, et al. Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. J Clin Oncol. 2014;32:1031-9 pubmed publisher

Lee A, Diasio R. Genetic biomarkers for Fluorouracil toxicity prediction: the long road to clinical utility. J Clin Oncol. 2014;32:989-90 pubmed publisher

Sclafani F, Gonzalez D, Cunningham D, Hulkki Wilson S, Peckitt C, Giralt J, et al. RAS mutations and cetuximab in locally advanced rectal cancer: results of the EXPERT-C trial. Eur J Cancer. 2014;50:1430-6 pubmed publisher

Xing L, Liang Y, Zhang J, Wu P, Xu D, Liu F, et al. Definitive chemoradiotherapy with capecitabine and cisplatin for elder patients with locally advanced squamous cell esophageal cancer. J Cancer Res Clin Oncol. 2014;140:867-72 pubmed publisher

Miranda M, Hartmann J, Al Batran S, Kripp M, Gencer D, Hochhaus A, et al. Mitomycin C and capecitabine in pretreated patients with metastatic gastric cancer: a multicenter phase II study. J Cancer Res Clin Oncol. 2014;140:829-37 pubmed publisher

Herbertson R, Tebbutt N, Lee F, Gill S, Chappell B, Cavicchiolo T, et al. Targeted chemoradiation in metastatic colorectal cancer: a phase I trial of 131I-huA33 with concurrent capecitabine. J Nucl Med. 2014;55:534-9 pubmed publisher

Hoff P, Saragiotto D, Barrios C, del Giglio A, Coutinho A, Andrade A, et al. Randomized phase III trial exploring the use of long-acting release octreotide in the prevention of chemotherapy-induced diarrhea in patients with colorectal cancer: the LARCID trial. J Clin Oncol. 2014;32:1006-11 pubmed publisher

Qiu M, Wei X, Zhang D, Jin Y, Zhou Y, Wang D, et al. Efficacy and safety of capecitabine as maintenance treatment after first-line chemotherapy using oxaliplatin and capecitabine in advanced gastric adenocarcinoma patients: a prospective observation. Tumour Biol. 2014;35:4369-75 pubmed publisher

Spindler K, Pallisgaard N, Andersen R, Ploen J, Jakobsen A. Gemcitabine and capecitabine for heavily pre-treated metastatic colorectal cancer patients--a phase II and translational research study. Anticancer Res. 2014;34:845-50 pubmed

Giotta F, Latorre A, Cramarossa A, Simone G, Florio C, Oliva S, et al. Rapid tumor shrinkage with lapatinib plus capecitabine in a patient with massive liver involvement. Tumori. 2013;99:278e-81e pubmed publisher

Sini V, Menghi A, Cursano M, Mandolini P, Lanza R. Over 17-month complete clinical brain response with a well-tolerated lapatinib plus capecitabine combination in a very young patient afflicted by HER2-positive metastatic breast cancer. Tumori. 2013;99:273e-7e pubmed publisher

Bianchi G, Duca M, Sica L, Mariani G. Metastatic breast cancer treated with lapatinib with a prolonged benefit: a case report and a review of therapeutic options available. Tumori. 2013;99:269e-72e pubmed publisher

Riccardi F, Mocerino C, Barbato C, Vitale M, Carrillo G, Trunfio M, et al. 18FDG-PET for early prediction of complete response to lapatinib and capecitabine in HER2-positive metastatic breast cancer: a case report. Tumori. 2013;99:257e-60e pubmed publisher

Wang J, Song P, Schrieber S, Liu Q, Xu Q, Blumenthal G, et al. Exposure-response relationship of T-DM1: insight into dose optimization for patients with HER2-positive metastatic breast cancer. Clin Pharmacol Ther. 2014;95:558-64 pubmed publisher

Meyer T, Qian W, Caplin M, Armstrong G, Lao Sirieix S, Hardy R, et al. Capecitabine and streptozocin ± cisplatin in advanced gastroenteropancreatic neuroendocrine tumours. Eur J Cancer. 2014;50:902-11 pubmed publisher

Chen F, Zhou X, Egbert B, Swetter S, Sarin K. Dermatomyositis associated with capecitabine in the setting of malignancy. J Am Acad Dermatol. 2014;70:e47-8 pubmed publisher

Yamanashi T, Nishi T, Yamamoto T, Toriumi F, Koshida Y, Mukai K, et al. [A case of endocrine cell carcinoma of the ascending colon with liver metastasis treated with hepatectomy after excision of the primary lesion and systemic chemotherapy]. Gan To Kagaku Ryoho. 2014;41:107-12 pubmed

Palacio S, Loaiza Bonilla A, Kittaneh M, Kyriakopoulos C, Ochoa R, Escobar M, et al. Successful use of Trastuzumab with anthracycline-based chemotherapy followed by trastuzumab maintenance in patients with advanced HER2-positive gastric cancer. Anticancer Res. 2014;34:301-6 pubmed

Tomoda M, Kawahara H, Watanabe K, Enomoto H, Akiba T, Yanaga K. Usefulness of monthly chemotherapy for patients with unresectable metastatic colorectal cancer. Anticancer Res. 2014;34:191-4 pubmed

Fujii C, Imamura H, Fukunaga M, Kamigaki S, Kimura Y, Kawase T, et al. [Efficacy of AboundTM for hand-foot syndrome caused by capecitabine]. Gan To Kagaku Ryoho. 2013;40:2457-9 pubmed

Noda S, Kashiwagi S, Kawajiri H, Takashima T, Onoda N, Hirakawa K. [A case of metastatic breast carcinoma of the cervical muscles]. Gan To Kagaku Ryoho. 2013;40:2405-7 pubmed

Makari Y, Iijima S, Doi T, Hoshi M, Oshima S, Ikeda K, et al. [Recurrent gastric cancer treated with fourth-line chemotherapy consisting of capecitabine and cisplatin leading to partial response]. Gan To Kagaku Ryoho. 2013;40:2265-7 pubmed

Deguchi K, Nishikawa K, Iwase K, Kawada J, Aono T, Yoshida H, et al. [A case of HER2-positive advanced gastric cancer successfully treated with a combination of capecitabine, cisplatin, and trastuzumab as first-line chemotherapy]. Gan To Kagaku Ryoho. 2013;40:2253-5 pubmed

Murayama M, Kohno T, Miyazawa M, Shimazaki A, Miyaki A, Usuda A, et al. [A case of a recurrent hepatic metastasis occurred after curative resection of ascending colon cancer and a hepatic metastasis responding completely to capecitabine plus bevacizumab]. Gan To Kagaku Ryoho. 2013;40:2014-6 pubmed

Iwata N, Ishikawa T, Takahashi H, Baba H, Masuda D, Okazaki S, et al. [A case of recurrent rectal cancer successfully treated for a long period with capecitabine plus oxaliplatin and bevacizumab therapy]. Gan To Kagaku Ryoho. 2013;40:2008-10 pubmed

Endo A, Yoshida Y, Nakashima R, Takahashi N, Tanabe K. Capecitabine induces both cardiomyopathy and multifocal cerebral leukoencephalopathy. Int Heart J. 2013;54:417-20 pubmed

Gao Y, An X, Sun W, Cai J, Cai M, Kong L, et al. Evaluation of capecitabine and oxaliplatin administered prior to and then concomitant to radiotherapy in high risk locally advanced rectal cancer. J Surg Oncol. 2014;109:478-82 pubmed publisher

Toshima T, Kodera M, Yamashita Y, Oishi M, Seshimo K, Yamamura M, et al. [A case in which dihydropyrimidine dehydrogenase deficiency was strongly suspected during adjuvant chemotherapy with capecitabine for colon cancer]. Gan To Kagaku Ryoho. 2013;40:1549-52 pubmed

Popa E, Shah M. Capecitabine in the treatment of esophageal and gastric cancers. Expert Opin Investig Drugs. 2013;22:1645-57 pubmed publisher

Kelly C, Bhuva N, Harrison M, Buckley A, Saunders M. Use of raltitrexed as an alternative to 5-fluorouracil and capecitabine in cancer patients with cardiac history. Eur J Cancer. 2013;49:2303-10 pubmed publisher

Polk A, Vaage Nilsen M, Vistisen K, Nielsen D. Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: a systematic review of incidence, manifestations and predisposing factors. Cancer Treat Rev. 2013;39:974-84 pubmed publisher

Saridaki Z, Lambrodimou G, Kachris S, Makrantonakis P, Boukovinas I, Polyzos A, et al. Postoperative treatment with docetaxel, cisplatin, and capecitabine (DCX) and chemoradiotherapy (CRT) with capecitabine for resected gastric adenocarcinoma. Am J Clin Oncol. 2015;38:17-22 pubmed publisher

Bajetta E, Pietrantonio F, Buzzoni R, Ferrario E, Valvo F, Mariani L, et al. Chronomodulated capecitabine and adjuvant radiation in intermediate-risk to high-risk rectal cancer: a phase II study. Am J Clin Oncol. 2014;37:545-9 pubmed publisher

Li Q, Jiang Y, Wei W, Yang H, Liu J. Clinical efficacy of including capecitabine in neoadjuvant chemotherapy for breast cancer: a systematic review and meta-analysis of randomized controlled trials. PLoS ONE. 2013;8:e53403 pubmed publisher

Yamauchi S, Nakagawa T, Kasahara M, Sugimoto H, Ishiba T, Tamura N, et al. [A case of metastatic breast cancer with bilateral hydronephrosis effectively treated with capecitabine]. Gan To Kagaku Ryoho. 2012;39:2077-9 pubmed

Bonotto M, Bozza C, Di Loreto C, Osa E, Poletto E, Puglisi F. Making capecitabine targeted therapy for breast cancer: which is the role of thymidine phosphorylase?. Clin Breast Cancer. 2013;13:167-72 pubmed publisher

Wang Y, Yang H, Wei J, Meng L. Efficacy and toxicity of capecitabine-based chemotherapy in patients with metastatic or advanced breast cancer: results from ten randomized trials. Curr Med Res Opin. 2012;28:1911-9 pubmed publisher

Deboever G, Hiltrop N, Cool M, Lambrecht G. Alternative treatment options in colorectal cancer patients with 5-fluorouracil- or capecitabine-induced cardiotoxicity. Clin Colorectal Cancer. 2013;12:8-14 pubmed publisher

Duman B, Paydas S, Tetiker T, Günaldi M, Afsar C, Ercolak V, et al. Capecitabine-induced hypertriglyceridemia and hyperglycemia: two cases. Pharmacology. 2012;90:212-5 pubmed publisher

Stanciu M, Aubut N, Gagne E, Thibeault M. Capecitabine-induced inflammation of actinic keratosis: case report and literature review. J Cutan Med Surg. 2012;16:298-9 pubmed

Fernandez Martos C, Nogue M, Cejas P, Moreno García V, Machancoses A, Feliu J. The role of capecitabine in locally advanced rectal cancer treatment: an update. Drugs. 2012;72:1057-73 pubmed publisher

O Shaughnessy J, Kaufmann M, Siedentopf F, Dalivoust P, Debled M, Robert N, et al. Capecitabine monotherapy: review of studies in first-line HER-2-negative metastatic breast cancer. Oncologist. 2012;17:476-84 pubmed publisher

Miles D, Zielinski C, Martin M, Vrdoljak E, Robert N. Combining capecitabine and bevacizumab in metastatic breast cancer: a comprehensive review. Eur J Cancer. 2012;48:482-91 pubmed publisher

Lau P, Zheng S, Ng W, Yu S. Inoperable pancreatic adenocarcinoma rendered complete remission by high-intensity focused ultrasound concurrent with gemcitabine-capecitabine chemotherapy: case report and topic review. J Dig Dis. 2012;13:60-4 pubmed publisher

Tunio M, Hashmi A, Shoaib M. Capecitabine induced cardiotoxicity: a case report and review of literature. Pak J Pharm Sci. 2012;25:277-81 pubmed

Hoesly F, Baker S, Gunawardane N, Cotliar J. Capecitabine-induced hand-foot syndrome complicated by pseudomonal superinfection resulting in bacterial sepsis and death: case report and review of the literature. Arch Dermatol. 2011;147:1418-23 pubmed publisher